XML 46 R16.htm IDEA: XBRL DOCUMENT v3.25.3
CONCENTRATIONS AND UNCERTAINTIES
 12 Months Ended
Aug. 31, 2025
Risks and Uncertainties [Abstract]  
CONCENTRATIONS AND UNCERTAINTIES CONCENTRATIONS AND UNCERTAINTIES
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. The Company holds cash and cash equivalents with balances that exceed FDIC-insured limits. Cash maintained in excess of these limits is on deposit with a large, national bank. Accordingly, the Company does not have depository exposure to regional banks. In addition, the Company holds cash at a bank in France that is not FDIC-insured. Historically, the Company has not experienced any losses in such accounts, and management believes that the financial institutions at which its cash is held are stable; however, no assurances can be provided. While the Company may be exposed to credit losses due to the nonperformance of its counterparties, the Company does not expect the settlement of these transactions to have a material effect on its results of operations, cash flows, or financial condition.
Revenue concentration shows that international sales accounted for 27%, 28%, and 31% of revenue for the fiscal years ended August 31, 2025, 2024, and 2023, respectively. Our three largest clients in terms of revenue accounted for 7%, 3%, and 3% of total revenues, respectively, for the fiscal year ended August 31, 2025. Our four largest clients in terms of revenue accounted for 7%, 3%, 3%, and 2% of total revenues, respectively, for the fiscal year ended August 31, 2024. Our three largest clients in terms of revenue accounted for 6%, 4%, and 3% of total revenues, respectively, for the fiscal year ended August 31, 2023.
Accounts receivable concentrations show that our three largest clients in terms of accounts receivable each comprised between 6% and 9% of accounts receivable as of August 31, 2025; our six largest clients in terms of accounts receivable comprised between 3% and 9% of accounts receivable as of August 31, 2024. As of the filing date of this report, our largest client, which represented 9% of accounts receivable as of August 31, 2025, was current on all outstanding invoices, except for a de minimis amount.
We operate in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.